We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 584

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

Federal Circuit issues seven opinions on patentability of software innovations

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The en banc Federal Circuit Court of Appeals has divided over whether method and computer-readable media claims and system claims are directed to

EU Medicines Agency plans to appeal interim rulings on release of clinical trial data

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

SCOTUS unanimously rules GM soybean patent infringed

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The U.S. Supreme Court has determined that the "exhaustion doctrine" does not apply in the context of a patented genetically modified (GM) seed, and

Rapid biosimilar growth seen through 2023

  • Shook Hardy & Bacon LLP
  • -
  • Global
  • -
  • May 16 2013

British market-research firm Visiongain has forecast a $2.445-billion global market for biosimilars in 2013, a 20-percent increase over 2012, with

Canada to invest in plant to convert oil sand GHGs into biofuels, other products

  • Shook Hardy & Bacon LLP
  • -
  • Canada
  • -
  • May 16 2013

The Government of Canada has reportedly formed a joint venture through the National Research Council of Canada with Canadian Natural Resources Ltd

Congress advances pharma supply chain and animal-drug user-fee laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level

Silicon Valley companies welcome new USPTO outpost

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

The U.S. Patent and Trademark Office (USPTO) has begun hiring judges who will staff its Silicon Valley regional office and expects to eventually hire

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy